Triple Peptide Vaccine

August 1, 2003
John Otrompke

Chicago - Data involving the first 60 patients in a phase II clinical trial of a multi-epitope peptide vaccination, as combined with other agents, showed a median survival of 21 months for immunological responders as compared to 13 months in immunologic nonresponders.

Related Content: